The increased survival time in ALS mice that either underwent US or US and IGF1 treatments, was due to an effect on the early disease phase duration, which was prolonged in the mice of the US-treated groups compared to that of mice in the control group and in mice in the US IGF1 group compared to mice in the IGF1 group (mean ± SD, US = 47.8 ± 10, control = 37.4 ± 10.6, p = 0.037, US IGF1 = 47 ± 8.8, IGF1 = 36.8 ± 8.8, p = 0.022, ANOVA followed by a post hoc Šídák multiple comparison test, Fig. 3c). Here, IGF1 is linked to amyotrophic lateral sclerosis.